Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00673881 · ClinicalTrials.gov registry record · Phase 1
ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study
A Phase 1 study of Dyslipidemia, sponsored by Radiant Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00673881 is a Phase 1 study of Dyslipidemia that has completed, run by Radiant Research. The registered enrollment target is 25 participants, below the 362-participant average among 40 other Dyslipidemia trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00673881, a Phase 1 study of Dyslipidemia, has completed, sponsored by Radiant Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of the study are: 1. To evaluate the effect of ABT-335 (choline fenofibrate) on several parameters of RCT (reverse cholesterol transport) in men and post-menopausal women diagnosed with dyslipidemia (i.e., low high-density lipoprotein \[HDL\] cholesterol levels and elevated triglyceride \[TG\] concentrations). 2. To evaluate longitudinal changes in several parameters of RCT in subjects with low HDL. 3. To obtain pilot data for power calculations for subsequent comparative study.
Conditions Studied
Interventions
- DRUG choline fenofibrate
Study Locations (1)
Illinois
- Radiant Research, 515 N State St, #2700 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00673881
The ClinicalTrials.gov registry entry for NCT00673881 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 362-participant average among 40 other Dyslipidemia trials with a reported enrollment target (93% lower). The listed sponsor is Radiant Research, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dyslipidemia appearing as the primary indexed condition, and to 1 intervention - of which choline fenofibrate is the first listed.
NCT00673881 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00673881 about?
NCT00673881 is a clinical study titled "ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study". The objectives of the study are: 1. To evaluate the effect of ABT-335 (choline fenofibrate) on several parameters of RCT (reverse cholesterol transport) in men and post-menopausal women diagnosed with dyslipidemia (i.e., low high-density lipoprotein \[HDL\] cholesterol levels and elevated triglycer...
What is the current status of trial NCT00673881?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2008-03. Estimated completion is 2009-05.
What conditions does trial NCT00673881 study?
This clinical trial studies the following conditions: Dyslipidemia.
What interventions are being tested in trial NCT00673881?
The interventions under investigation include: choline fenofibrate (DRUG).
Who is sponsoring clinical trial NCT00673881?
This trial is sponsored by Radiant Research, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00673881 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
RECRUITING · Phase 1
-
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
COMPLETED · Phase 1
-
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
COMPLETED · Phase 1
-
A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003
COMPLETED · Phase 1
-
Effects of Niacin On Fatty Acid Trapping
COMPLETED · Phase 1
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.